Communiqués Glaukos Corporation

Actions

GKOS

US3773221029

Equipement, fournitures et distribution médicale

Marché Fermé - NYSE 22:00:02 28/08/2026			Varia. 5j.	Varia. 1 janv.
179,87 ^USD	-1,12%		-2,72%	+59,30%

14/08	Un dirigeant de Glaukos cède des actions pour un montant de 10 784 659 $, selon un récent document de la SEC	MT
11/08	Glaukos : un dirigeant cède des actions pour un montant de 3 602 600 $, selon une déclaration à la SEC	MT

Communiqués

19/08	Glaukos Announces Participation in Wells Fargo Healthcare Conference	BU
29/07	Glaukos: Q2 Earnings Snapshot	AQ
29/07	Glaukos : Second Quarter 2026 GAAP to Non-GAAP Recs	PU
29/07	Glaukos Announces Second Quarter 2026 Financial Results	BU
27/07	Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt	BU
08/07	Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29	BU
25/06	Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis	BU
12/05	Glaukos Announces Participation in Upcoming Investor Conferences	BU
04/05	Glaukos : Investor Presentation May 2026	PU
29/04	Glaukos: Q1 Earnings Snapshot	AQ
29/04	Glaukos : First Quarter 2026 Quarterly Summary	PU
29/04	Glaukos : First Quarter 2026 GAAP to Non-GAAP Recs	PU
29/04	Glaukos Announces First Quarter 2026 Financial Results	BU
16/04	Glaukos Announces the Release of its 2025 Sustainability Report	BU
15/04	Glaukos Receives Permanent J-code for Epioxa™	BU
08/04	Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29	BU
06/04	Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	BU
20/03	Glaukos Announces Commercial Availability of Epioxa, a Transformative Innovation in Interventional Keratoconus Care	AQ
19/03	Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care	BU
02/03	Glaukos : Investor Presentation March 2026	PU
23/02	Glaukos : Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K)	PU
17/02	Glaukos: Q4 Earnings Snapshot	AQ
17/02	Glaukos : Fourth Quarter 2025 Quarterly Summary	PU
17/02	Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results	BU
29/01	Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose TR	AQ